U.S. SEVERE ORAL MUCOSITIS MARKET ANALYSIS

Oral mucositis refers to tissue swelling in the mouth. Radiation therapy or chemotherapy may cause mucositis. Oral mucositis is an erythematous and ulcerative lesion of the oral mucosa observed in patients with cancer who are treated with chemotherapy, and/or with radiation therapy. Lesions of oral mucositis are often very painful and compromise nutrition and oral hygiene as well as increase the risk for local and systemic infection. Oral mucositis is a significant and dose-limiting toxicity of cancer therapy with important clinical and economic implications. Oral mucositis from chemotherapy or radiation treatment can last from 7 to 98 days.

Market Dynamics

The key players in the market are focused on growth strategies such as FDA approvals, which are expected to drive the growth of the market over forecast period. For instance, in November 2016, Oragenics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AG013, the company’s lead therapeutic candidate for the treatment of oral mucositis. Furthermore, in April 2018, Enzychem Lifesciences announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to EC-18 for the treatment of chemo-radiation induced oral mucositis. Moreover, key companies focusing on research and development of severe oral mucositis are expected to drive the growth of the market over forecast period. For instance, in December 2019, Oragenics, Inc., announced the completion of enrolment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, which is an easy-to-use oral rinsing system designed to prevent and treat oral mucositis.

Key features of the study

• This report provides in-depth analysis of the U.S. severe oral mucositis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. severe oral mucositis market based on the following parameters – Company Highlights, financial performance, product portfolio, market presence, distribution strategies, Key Highlights, strategies, and future plans
• Key companies covered as a part of this study include Innovation Pharmaceuticals Inc.*, Monopar Therapeutics Inc., Soligenix, Inc., Oragenics, Inc., Enzychem Lifesciences, Galera Therapeutics, Inc., Amgen, Inc., and Covis Pharma Group.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S. severe oral mucositis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. severe oral mucositis market.

Market Segmentation

• By Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Palifermin
  • Amifostine
  • Chlorhexidine
  • Sucralfate
  • Late Phase (Avasopasem and Dusquetide)
• By Cause Insights (Revenue, USD Mn, 2021 - 2033)
  • Chemotherapy
  • Radiotherapy
• By Grade Insights (Revenue, USD Mn, 2021 - 2033)
  • Grade III
  • Grade IV
• By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Key Players
  • Innovation Pharmaceuticals Inc.
  • Monopar Therapeutics Inc.
  • Soligenix, Inc.
  • Oragenics, Inc.
  • Enzychem Lifesciences
  • Galera Therapeutics, Inc.
  • Amgen, Inc.
  • Covis Pharma Group.